|
|
Post by pearljamten on Mar 13, 2017 17:16:03 GMT -5
Can we allocate where the monthly 10 million is being spent?
|
|
|
|
Post by matt on Mar 14, 2017 7:39:40 GMT -5
It is broken out in the 10Q for you. Numbers before Q3 had a mixture of Sanofi and Mannkind in there, so not reliable for future forecasting, but Q3 is close to pure Mannkind and when earnings release later this week you can back into the numbers for Q4.
For Q3 it was roughly $4.3 for product cost, 3.9 for R&D, and 13.1 for selling & administrative expenses. There were other expenses reported as well, but I think those were accounting entries recording cash that had been spent in earlier periods. The R&D number includes new product development (that TS deal came with some costs remember) and continued development of Afrezza (most companies include medical trials in R&D expense). The line to watch, in my opinion, is selling & administrative cost. YTD Q3 2016 the number was slightly down when compared to YTD Q3 2015 even though Sanofi was doing all the sales and marketing in 2015. If sales are going to increase then more money has to be spent in this area.
|
|
